Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11458104 | MISSION PHARMACAL CO | NA |
Nov, 2038
(15 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
ODE* (ODE*) | Jun 28, 2026 |
Market Authorisation Date: 28 June, 2019
Treatment: A method of treating cystinuria by orally administering tiopronin with food to prevent cystine stone formation in adults and pediatric patients with severe homozygous cystinuria
Dosage: TABLET, DELAYED RELEASE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic